Extensive ERG11 mutations associated with fluconazole-resistant Candida albicans isolated from HIV-infected patients

Document Type : Original Articles


1 Department of Microbiology, Tagore Medical College and Hospital, Rathinamangalam, Chennai, India

2 Department of Microbiology, Saveetha Medical College and Hospital, Chennai, India


Background and Purpose: Azoles are preferred antifungal agents given their inexpensiveness, limited toxicity, and potentiality of oral administration. However, the extensive use of prophylactic azole therapy for chronic infections, especially in immunocompromised patients, has led to an increase in azole resistance, thereby rising health care costs. Fluconazole resistance is associated with poor clinical outcomes and the emergence of new infections. The present study aimed to investigate the mutations of ERG11 gene in fluconazole-resistant Candida albicans isolates.
Materials and Methods: This study was conducted on 80 clinical samples collected from HIV-infected patients with suspected candidiasis in Tagore Medical College Hospital and Government Hospital of Thoracic Medicine, Chennai, India, for a period of 18 months (May 2016-December 2017). The antifungal susceptibility pattern was determined by agar diffusion and broth dilution techniques as per the Clinical and Laboratory Standards Institute guidelines. The ERG11 gene of the known fluconazole-resistant strains of C. albicans was amplified by polymerase chain reaction (PCR). In addition, the samples were subjected to sequencing and mutation analysis.
Results: A total of 60 Candida species were isolated from HIV patients and were speciated using standard, conventional, and molecular methods. Candida albicans comprised 28.3% (n=17) of the Candida isolates, 59% (n=10) of which were resistant to fluconazole. Sequencing of the amplified product of ERG11 C. albicans gene isolates showed that they were highly mutated and included many nonsense mutations which were not reported earlier.
Conclusion: The molecular characterization of ERG11 gene showed many missense and nonsense mutations. Such mutations, which were unique to the geographical area under investigation, could be concluded to account for the development of resistance to fluconazole.


1. Centres for Disease Control and Prevention (US). Antibiotic resistance threats in the United States, 2013. New York: Centres for Disease Control and Prevention, US Department of Health and Human Services; 2013.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999; 29(2):239-44. 
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003; 37(9):1172-7. 
4. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the centres for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29(11):996-1011.
5. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302(21):2323-29. 
6. Davoudi AR, Najafi N, Hoseini Shirazi M, Ahangarkani F. Frequency of bacterial agents isolated from patients with nosocomial infection in teaching hospitals of Mazandaran University of Medical Sciences in 2012. Caspian J Intern Med. 2014; 5(4):227-31.
7. Eggimann P, Bille J, Marchetti O. Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care. 2011; 1:37.
8. Ji H, Zhang W, Zhou Y, Zhang M, Zhu J, Song Y, et al. A three dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem. 2000; 43(13):2493-505.
9. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, et al. Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology. 1999; 145(Pt 10):2701-13.
10. Podust LM, Poulos TL, Waterman MR. Crystal structure of cytochrome P450 14a -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci U S A. 2001; 98:3068-73.
11. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14 a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998; 42(2):241-53.
12. Nabili M, Abdollahi Gohar A, Badali H, Mohammadi R, Moazeni M. Amino acid substitutions in Erg11p of azole-resistant Candida glabrata: possible effective substitutions and homology modelling. J Glob Antimicrob Resist. 2016; 5:42-6.
13. Xu Y, Chen L, Li C. Suceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother. 2008; 61(4):798-804.
14. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization–time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and E test method. J Clin Microbiol. 2015; 53(6):1823-30.
15. CLSI. Method for Antifungal disc diffusion Susceptibility testing of yeasts. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2009.
16. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. CLSI document M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008.
17. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillán RA, Martínez M, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high level fluconazole resistance isolated from human immunodeficiency virus infected patients. Antimicrob Agents Chemother. 2001; 45(10):2676-84. 
18. Wadhwa A, Kaur R, Agarwal SK, Jain S, Bhalla P. AIDS-related opportunistic mycoses seen in a tertiary care hospital in North India. J Med Microbiol. 2007; 56(Pt 8):1101-6. 
19. Nagalingeswaran K, Solomon S, Madhivanan P, Yepthomi T, Venkatesan C, Amalraj E, et al. Correlation between plasma viral load and CD4+T cell count to opportunistic infections in persons with HIV in South India. Int Conf AIDS. 2000; 13:9-14. 
20. Pruthvi BC, Vikram S, Suman SK, Jayaprakash B, Rau NR. Spectrum of clinical presentation and opportunistic infections in HIV: an Indian scenario. Int J Infect Dis. 2008; 12:e484. 
21. Pandey S, Sundar S, Hasan H, Shankar R, Singh RP. Clinical profile and opportunistic infection in HIV/AIDS patients attending SS Hospital, Varanasi. Indian J Prev Soc Med. 2008; 39(1):I2. 
22. Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci. 2003; 57(1):16-21. 
23. Deorukhkar S, Saini S, Stephen M. Non-albicans Candida infections: an emerging threat. Interdiscip Perspect Infect Dis. 2014; 2014:615958. 
24. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100(6):617-23.
25. Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis. 2004; 50(1):25-32.
26. Lamb DC, Kelly DE, Schunck WH, Shyadehi AZ, Akhtar M, Lowe DJ, et al. The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem. 1997; 272(9):5682-8.
Volume 5, Issue 3
September 2019
Pages 1-6
  • Receive Date: 09 February 2019
  • Revise Date: 05 May 2019
  • Accept Date: 31 July 2019
  • First Publish Date: 01 September 2019
  • Publish Date: 01 September 2019